Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results